Alnylam Pharmaceuticals announced this week that it has filed with UK regulators to begin phase I testing of a subcutaneous version of its TTR-mediated amyloidosis treatment called ALN-TTRsc.

Currently, Alnylam is testing an intravenously delivered form of the drug called ALN-TTR02, which it anticipates entering phase III testing by the end of this year. However, the firm has long been planning to incorporate its GalNAc conjugate delivery technology into its TTR amyloidosis program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.